Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA)

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3tWX61P
via IFTTT